Clearside Biomedical, Inc. (CLSD)
Clearside Biomedical, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Alpharetta, GA, US. The stock last traded at $0.41, up 0.00% on the session, giving a market capitalisation of $2.1M. On trailing twelve-month figures it carries a trailing P/E of -0.11, a net margin of -618.3%. Its beta of 1.79 implies it has historically moved more than the broad market.
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space. Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema. The company's development pipeline also features CLS-AX, an axitinib injectable suspension administered into the suprachoroidal space, which is currently undergoing Phase 1/2a clinical trials. Additionally, they are advancing CLS-301, an integrin inhibitor suspension aimed at addressing diabetic macular edema and macular degeneration. Clearside maintains strategic partnerships with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Established in 2011, Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.
Clearside Biomedical, Inc. is most often compared with the following Healthcare names: